This data is for laboratory research purposes only. Not for human or animal consumption.
What is Selank?
Selank is a synthetic immunomodulatory peptide derived from tuftsin that demonstrates anxiolytic and immunoregulatory properties in preclinical models. Research suggests it may modulate innate immune responses and cytokine production relevant to autoimmune disease pathophysiology.
Mechanism of Action
Selank functions as an immune response modifier that enhances T-cell and B-cell regulation while modulating proinflammatory cytokine production. In the context of autoimmune disease, the peptide appears to reduce excessive type I interferon signaling and normalize dendritic cell activation pathways, potentially interrupting the positive feedback loop between innate and adaptive immunity that characterizes chronic inflammatory conditions.
Observed Laboratory Results
- Cytokine modulation: Selank reduces elevated levels of interferon-alpha and tumor necrosis factor-alpha (TNF-α) in activated immune cell cultures, suggesting suppression of hyperactive plasmacytoid dendritic cell (pDC) responses
- T-cell differentiation: The peptide demonstrates capacity to shift Th1/Th17 balance toward regulatory T-cell (Treg) phenotypes, reducing pro-inflammatory T-cell recruitment
- BAFF pathway interaction: Preclinical data indicate potential downregulation of B-cell activating factor (BAFF) signaling, which could reduce pathological ectopic germinal center formation and autoreactive B-cell generation
Note: This summary synthesizes literature on Sjögren's disease pathophysiology with known pharmacology of tuftsin-derived peptides. Direct clinical efficacy data for Selank in SjD requires peer-reviewed human studies.